New preclinical data further support ongoing programs and highlight next generation of immunotherapies
Partner MedImmune expands colorectal cancer patient cohort in ongoing Phase I trial evaluating monalizumab in combination with Imfinzi® (durvalumab)
Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018
Innate Pharma Hosts R&D Day Today in London
ICI conference 2017: new preclinical data further strengthen the rationale of IPH5401 and monalizumab for cancer treatments and in combination with anti-PD-1/PD-L1
Clinical and preclinical data on monalizumab to be presented at AACR annual meeting 2017
First clinical data for monalizumab as a single agent in cancer patients show favorable safety profile
Innate Pharma investor conference call on November 14, 2016 to discuss recent new clinical data
New data presented at AACR support the rationale for combination treatment with monalizumab and durvalumab
AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology
